Decreasing the adverse effects of cancer therapy: National Cancer Institute guidance for the clinical development of radiation injury mitigators.
Recently, many agents have been identified that target molecular pathways that can mitigate radiation toxicity. To date, no drugs have been approved as radiation injury mitigators, which are defined as agents administered after irradiation but before toxicity is manifest. In order to accelerate the application of potential mitigators for cancer patients, a meeting sponsored by the National Cancer Institute (NCI) and National Institute of Allergy and Infectious Diseases (NIAID) was held in January 2010. This article presents an algorithm to guide clinical trials for such agents in patients receiving radiotherapy or radiochemotherapy. It reviews the mechanisms of radiation injury, the clinical problem, the preclinical and clinical development of candidate agents, and the design and conduct of clinical trials. The central role of patient reported outcomes is outlined, as well as key lessons learned from prior clinical trials. Ultimately, the goal is to be able to apply such promising agents to improve the quality of life for patients receiving radiotherapy or chemoradiotherapy for cancer.
Department of Radiation Oncology, Henry Ford Hospital, Detroit, Michigan 48202, USA. bmovsas1@hfhs.org
Benjamin
B
Movsas
Bhadrasain
B
Vikram
Martin
M
Hauer-Jensen
John E
JE
Moulder
Ethan
E
Basch
Stephen L
SL
Brown
Lisa A
LA
Kachnic
Adam P
AP
Dicker
C Norman
CN
Coleman
Paul
P
Okunieff
D000465:Algorithms; D002986:Clinical Trials as Topic; D015195:Drug Design; D006801:Humans; D009369:Neoplasms / Q000523:psychology / Q000532:radiotherapy*; D011788:Quality of Life; D011832:Radiation Injuries / Q000517:prevention & control*; D011878:Radiotherapy / Q000009:adverse effects*; D014481:United States